Brocker P, Vellas B, Albarede J L, Poynard T
CHU Nice, Hôpital de Cantaron, La Trinité, France.
Age Ageing. 1994 Jul;23(4):303-6. doi: 10.1093/ageing/23.4.303.
In a double-blind trial, 194 ambulatory elderly patients (mean age, 74 +/- 8 years) recovering from acute illnesses were randomly assigned to receive either ornithine oxoglutarate (OGO) or a placebo. Nine subjects withdrew during the study, six in the OGO group and three in the placebo group. OGO and the placebo were administered once daily at a dose of 10 g after lunch for 2 months; the patients were monitored for a total of 4 months. Efficacy was evaluated in terms of nutritional variables, quality of life and total cost of medical treatment. The analysis involved a total of 185 patients (93 in the placebo group and 92 in the OGO group). The two groups were comparable at inclusion. After 30 and 60 days of treatment, there was a significant improvement in the following variables in the OGO group relative to the placebo group: appetite (p < 0.001), body weight (p < 0.001) and independence (p < 0.01). Two months after the end of treatment, there was still a significant improvement in the quality-of-life index (p < 0.001) and the medical-cost index (p < 0.03) in the OGO group, with an overall cost saving of 37%. We conclude that OGO seems to be a cost-effective nutritional supplement for elderly convalescent patients.
在一项双盲试验中，194名从急性疾病中康复的非卧床老年患者（平均年龄74±8岁）被随机分配接受鸟氨酸α-酮戊二酸（OGO）或安慰剂。9名受试者在研究期间退出，OGO组6名，安慰剂组3名。OGO和安慰剂均在午餐后每日一次，以10克的剂量给药，持续2个月；对患者总共监测4个月。根据营养变量、生活质量和医疗总费用评估疗效。分析共涉及185名患者（安慰剂组93名，OGO组92名）。两组在纳入时具有可比性。治疗30天和60天后，与安慰剂组相比，OGO组在以下变量方面有显著改善：食欲（p<0.001）、体重（p<0.001）和独立性（p<0.01）。治疗结束两个月后，OGO组的生活质量指数（p<0.001）和医疗费用指数（p<0.03）仍有显著改善，总体成本节省37%。我们得出结论，OGO似乎是老年康复患者一种具有成本效益的营养补充剂。
